Outlook Therapeutics Inc (OTLK)
6.04
-0.01
(-0.17%)
USD |
NASDAQ |
Nov 04, 16:00
6.16
+0.12
(+1.99%)
Pre-Market: 09:05
Outlook Therapeutics Enterprise Value: 143.29M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 143.29M |
| November 01, 2024 | 143.52M |
| October 31, 2024 | 136.66M |
| October 30, 2024 | 136.90M |
| October 29, 2024 | 136.19M |
| October 28, 2024 | 136.66M |
| October 25, 2024 | 129.09M |
| October 24, 2024 | 126.97M |
| October 23, 2024 | 125.07M |
| October 22, 2024 | 131.46M |
| October 21, 2024 | 135.01M |
| October 18, 2024 | 126.02M |
| October 17, 2024 | 122.00M |
| October 16, 2024 | 123.18M |
| October 15, 2024 | 121.52M |
| October 14, 2024 | 120.81M |
| October 11, 2024 | 122.23M |
| October 10, 2024 | 117.27M |
| October 09, 2024 | 117.50M |
| October 08, 2024 | 123.89M |
| October 07, 2024 | 121.29M |
| October 04, 2024 | 124.13M |
| October 03, 2024 | 124.60M |
| October 02, 2024 | 124.60M |
| October 01, 2024 | 123.89M |
| Date | Value |
|---|---|
| September 30, 2024 | 126.73M |
| September 27, 2024 | 131.93M |
| September 26, 2024 | 134.77M |
| September 25, 2024 | 130.99M |
| September 24, 2024 | 132.41M |
| September 23, 2024 | 132.41M |
| September 20, 2024 | 142.34M |
| September 19, 2024 | 142.34M |
| September 18, 2024 | 140.69M |
| September 17, 2024 | 143.29M |
| September 16, 2024 | 140.69M |
| September 13, 2024 | 153.46M |
| September 12, 2024 | 153.93M |
| September 11, 2024 | 166.71M |
| September 10, 2024 | 184.68M |
| September 09, 2024 | 189.89M |
| September 06, 2024 | 188.47M |
| September 05, 2024 | 185.39M |
| September 04, 2024 | 174.39M |
| September 03, 2024 | 159.85M |
| August 30, 2024 | 174.28M |
| August 29, 2024 | 173.09M |
| August 28, 2024 | 178.53M |
| August 27, 2024 | 177.11M |
| August 26, 2024 | 182.08M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
28.89M
Minimum
Dec 30 2019
564.16M
Maximum
Feb 08 2021
225.31M
Average
209.88M
Median
Enterprise Value Benchmarks
| Imunon Inc | 8.805M |
| Cormedix Inc | 535.86M |
| Brainstorm Cell Therapeutics Inc | 6.099M |
| Predictive Oncology Inc | -0.5069M |
| NovaBay Pharmaceuticals Inc | 3.645M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 44.41M |
| Total Expenses (Quarterly) | 19.56M |
| EPS Diluted (Quarterly) | -0.89 |
| Earnings Yield | -178.3% |
| Normalized Earnings Yield | -700.96 |